Enter any ticker symbol here to see the live quote & chart tools in action Ticker:

Benefits: / Your filings are automatically published to your site as they are filed. Investors don't have to leave your site to see filings. Product Description Once a report has been filed with the SEC it will be available on the website. SEC Filings Section 16 Filings Only   NOVADEL PHARMA INC filed this S-3/A on 02/02/2009. Click on link to view section or document 1. Entire Document including Exhibit(s) 2. S-3/A PAGE: 1 - CALCULATION OF REGISTRATION FEE PAGE: 2 - Subject to Completion, dated February 2, 2009 PAGE: 3 - PAGE: 4 - PROSPECTUS SUMMARY PAGE: 5 - PAGE: 6 - About the Initial Closing PAGE: 7 - PAGE: 8 - About the Subsequent Closing PAGE: 9 - PAGE: 10 - About the 8,934,075 shares subject to registration under this Registration Statement PAGE: 11 - PAGE: 12 - Prior Securities Transactions between the Company and the Purchasers PAGE: 13 - About NovaDel PAGE: 14 - Product Pipeline PAGE: 15 - PAGE: 16 - PAGE: 17 - NitroMist (nitroglycerin lingual aerosol) PAGE: 18 - Zensana (ondansetron oral spray) PAGE: 19 - Zolpimist for Middle-of-the-Night Awakenings (MOTN). PAGE: 20 - Fentanyl orals spray (NVD-501) PAGE: 21 - PAGE: 22 - RISK FACTORS PAGE: 23 - WE WILL REQUIRE SIGNIFICANT CAPITAL FOR PRODUCT DEVELOPMENT AND COMMERCIALIZATION IN THE NEAR TERM. PAGE: 24 - WE ARE A PRE-COMMERCIALIZATION COMPANY, HAVE A LIMITED OPERATING HISTORY AND HAVE NOT GENERATED ANY PAGE: 25 - THERE ARE CERTAIN INTERLOCKING RELATIONSHIPS AND POTENTIAL CONFLICTS OF INTEREST. PAGE: 26 - OUR BUSINESS AND REVENUE IS DEPENDENT ON THE SUCCESSFUL DEVELOPMENT OF OUR PRODUCTS. PAGE: 27 - WE HAVE NOT COMPLETED PRODUCT DEVELOPMENT. PAGE: 28 - WE MUST COMPLY WITH GOOD MANUFACTURING PRACTICES. PAGE: 29 - COMPLIANCE WITH CHANGING REGULATION OF CORPORATE GOVERNANCE AND PUBLIC DISCLOSURE MAY RESULT IN ADDI PAGE: 30 - EXTENSIVE GOVERNMENT REGULATION MAY AFFECT OUR BUSINESS. PAGE: 31 - OUR STRATEGY INCLUDES ENTERING INTO COLLABORATION AGREEMENTS WITH THIRD PARTIES FOR CERTAIN OF OUR P PAGE: 32 - IF WE CANNOT PROTECT OUR INTELLECTUAL PROPERTY, OTHER COMPANIES COULD USE OUR TECHNOLOGY IN COMPETIT PAGE: 33 - EVEN IF WE OBTAIN PATENTS TO PROTECT OUR PRODUCTS, THOSE PATENTS MAY NOT BE SUFFICIENTLY BROAD AND O PAGE: 34 - WE RELY ON CONFIDENTIALITY AGREEMENTS THAT COULD BE BREACHED AND MAY BE DIFFICULT TO ENFORCE. PAGE: 35 - RISKS RELATED TO OUR COMMON STOCK PAGE: 36 - WE ARE INFLUENCED BY CURRENT STOCKHOLDERS, OFFICERS AND DIRECTORS. PAGE: 37 - BECAUSE THE AVERAGE DAILY TRADING VOLUME OF OUR COMMON STOCK IS LOW, THE ABILITY TO SELL OUR SHARES PAGE: 38 - SHARES ELIGIBLE FOR FUTURE SALE MAY ADVERSELY AFFECT THE MARKET. PAGE: 39 - LIMITATION ON DIRECTOR/OFFICER LIABILITY. PAGE: 40 - THE SECURITIES ISSUED IN OUR DECEMBER 2006 PRIVATE PLACEMENT AND OUR 2008 PRIVATE PLACEMENT ARE REST PAGE: 41 - THE UNCERTAINTY CREATED BY CURRENT ECONOMIC CONDITIONS AND POSSIBLE TERRORIST ATTACKS AND MILITARY R PAGE: 42 - USE OF PROCEEDS PAGE: 43 - PAGE: 44 - PLAN OF DISTRIBUTION PAGE: 45 - PAGE: 46 - LEGAL MATTERS PAGE: 47 - INFORMATION INCORPORATED BY REFERENCE PAGE: 48 - 8,934,075 Shares of Common Stock PAGE: 49 - PART II PAGE: 50 - Item 16. Exhibits. PAGE: 51 - Item 17. Undertakings. PAGE: 52 - PAGE: 53 - PAGE: 54 - SIGNATURES PAGE: 55 - PAGE: 56 - EXHIBIT INDEX 3. EX-5.1 - Opinion regarding legality PAGE: 1 - Exhibit 5.1 4. EX-23.1 - Consents of experts and counsel PAGE: 1 - Exhibit 23.1 Quote & Chart Package Basic Stock Chart Basic Stock Quote Embedded Quote / Chart Embedded Full Quote / Chart Interactive Chart Intraday Chart Pop Up Quote Scrolling Ticker You are viewing our Quote and Chart Demo using ticker symbol NVDL

T 800.650.1211     F 888.329.6696     E info@stockgroup.com   © 2004 Stockgroup Media Inc.    Disclaimer